Pinsents and Linklaters act on latest big pharma deal as Teva sells Allergan generics business for £600m Legal Business6 October 2016Corporate and M&ADeal watch Pinsent Masons and Linklaters are advising on Teva Pharmaceutical Industries’ sale of UK and Ireland business Activas Generics for £603m as the Israeli firm seeks to divest assets following last year’s takeover of Allergan.Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryThe Slaughters standard: what makes a top quality partner?Kirkland, Simpson Thacher and Latham top LSEG PE rankings as partners look ahead to 2026Revolving Doors: Sidley and Hogan Lovells swipe Latham partners, as Ropes and Clifford Chance build in EuropeBeyond the deals: how clients rate London’s top M&A teamsFreshfields and Slaughters among international line-up on €5bn Deutsche Börse dealRopes and Kirkland lead on EQT’s $3.7bn acquisition of secondaries leader CollerDealwatch: Global 100 advisers take centre stage on BlackRock-GIP $12.5bn mega dealDealwatch: Telegraph auction off as Barclay brothers pay off Lloyds debt with loanDeal Watch: activity powers on as Latham and A&O lead on $19bn energy joint venture